Background There have been no reports on the incidence, characteristics, treatment outcomes, and prognosis of inoperably advanced or recurrent adenocarcinoma of the esophagogastric junction (AEGJ) in Japan. Methods We investigated the clinicopathological characteristics, treatment outcomes, and prognosis for 816 patients with esophagogastric junctional and gastric adenocarcinoma who received first-line chemotherapy between 2004 and 2009. Results Of 816 patients, 82 (10 %) had AEGJ. The patients with AEGJ had significantly more lung and lymph node metastasis, but less peritoneal metastasis, than those with gastric adenocarcinoma (GAC). The objective response rate to first-line chemotherapy was 23.3 % for patients with AEGJ and 22.6 % in patients with GAC (p = 0.90). The median survival was 13.0 months in AEGJ and 11.8 months in GAC (p = 0.445). In no patient was tumor site a significant prognostic factor (p = 0.472). In patients with AEGJ, ECOG PS C 2, presence of liver metastasis, and absence of lung metastasis were significantly associated with poor prognosis. Conclusions No significant differences were observed in treatment outcomes between advanced AEGJ and GAC. Therefore, the same chemotherapy regimen can be given as a treatment arm in future Japanese clinical trials to both patients with inoperably advanced or recurrent AEGJ and those with GAC.
Introduction
Adenocarcinoma of the esophagogastric junction (AEGJ) or lower esophagus is one of the most rapidly increasing malignant diseases in the West and appears to have a different etiology from distal gastric cancer [1] [2] [3] [4] . In contrast, the incidence of AEGJ is unchanged or only gradually increasing in the East [5] [6] [7] , and its clinicopathological features have not yet been elucidated, especially in advanced, nonresectable tumors.
From clinical trials for advanced cancers of the esophagus and the stomach, the current status of AEGJ is variable; it may be treated as either esophageal or gastric cancer, or be excluded from the trial altogether. Chau et al. [8] studied 1,775 patients with advanced esophagogastric cancer, including 457 with AEGJ, who had been treated with chemotherapy in four Western randomized trials. That study found no difference in overall survival (OS), response rates, or toxicities by tumor location.
In Japanese randomized trials for advanced esophageal or gastric cancer, AEGJ has not been specifically examined because of its rarity [9] [10] [11] [12] [13] . There is currently no standard chemotherapy regimen for AEGJ, and it is usually treated as a gastric cancer with fluoropyrimidine and platinum.
In this study, we retrospectively investigated clinicopathological features and treatment outcomes associated with advanced AEGJ in Japanese patients treated at a highvolume cancer center, examining whether AEGJ warrants a separate clinical approach in future clinical trials.
Patients and methods

Patients
We retrospectively analyzed patients with inoperably advanced or recurrent gastric and esophageal cancer who had received palliative therapy between January 2004 and December 2009 at the National Cancer Center Hospital in Tokyo. The eligibility criteria for this study were as follows: (1) histologically confirmed adenocarcinoma; (2) treatment with first-line chemotherapy in our hospital; and (3) availability of clinicopathological data at the beginning of the first-line chemotherapy. Carcinomas in remnant stomach after partial gastrectomy were excluded. Of 1,395 patients who received palliative therapy in our hospital between 2004 and 2009, 816 patients were enrolled in this study (Fig. 1) . All endpoints were updated in March 2011. Median follow-up time was 11.1 months (range, 0.8-82.0 months), and median follow-up time for the surviving patients was 19.0 months.
Clinicopathological data
Performance status (PS) at the beginning of first-line chemotherapy was evaluated according to the Eastern Cooperative Oncology Group criteria. Clinical tumor response was assessed according to Response Evaluation Criteria in Solid Tumors (RECIST ver. 1.0). The histological type of the primary tumor was evaluated by using a biopsy specimen of inoperably advanced cases and the surgical specimen of recurrent cases. Histological type was determined according to the Japanese classification for gastric carcinoma for the predominant histological type [14] . Papillary, well-or moderately differentiated adenocarcinoma was defined as the intestinal type, whereas poorly differentiated adenocarcinoma or signet-ring cell carcinoma was defined as the diffuse type. Mucinous adenocarcinoma was classified as intestinal or diffuse depending on the secondary predominant histological type.
Baseline characteristics at the beginning of first-line chemotherapy such as age, sex, PS, and laboratory data were evaluated. The following clinicopathological factors were also evaluated: disease status (inoperably advanced or recurrent), histopathology (intestinal or diffuse), metastatic site at the beginning of first-line chemotherapy (liver, peritoneum, lung, bone, abdominal lymph node, mediastinal lymph node, and cervical lymph node), number of metastatic sites, and response to first-line chemotherapy.
AEGJ classification
The tumor location of AEGJ was defined in accordance with Siewert's classification [15] . The Siewert subtypes were retrospectively determined by the following method. In recurrent patients, pathologists recorded the relationship between the tumor center and EGJ according to Siewert's classification, when diagnosing the surgically resected specimen. In inoperably advanced patients, two endoscopists retrospectively determined the relationship between the EGJ and the tumor center independently of each other.
Statistical analysis
Statistical analysis was performed using SPSS 17.0 statistical software (SPSS, Chicago, IL, USA). Comparison of categorical variables was tested by the Chi square test. OS was calculated from the date of the first diagnosis of inoperably advanced or recurrent gastric cancer to death from any cause that was scored as an event. Patients who were alive were censused at the last follow-up date. Survival curves were derived from Kaplan-Meier estimates, and the curves were compared by log-rank tests. A prognostic model was established by searching all variables that significantly influenced OS at a level of p values \0.05 in the univariate analysis. Multivariate analysis for OS was performed using stepwise Cox's proportional hazard regression model (entry probability 0.05, removal probability 0.1). All the tests were two sided, and p values \0.05 were considered significant. Figure 2 shows that there were no significant differences in OS between AEGJ and GAC (log-rank, p = 0.445). In the patients treated by the F ? P regimen, which is the standard therapy for gastric and esophageal cancer, the survival time was not significantly different between the patients with AEGJ and those with GAC (log-rank, p = 0.352).
In no patient was tumor site (EGJ or gastric) a significant prognostic factor (p = 0.472). The results of univariate analysis of clinicopathological variables for prognostic factors in patients with AEGJ and GAC are shown in Table 2 . In univariate analysis, four variables were significantly associated with poor survival time in patients with GAC: ECOG PS B 2, inoperably advanced disease status, diffuse histopathology, and two or more metastatic sites. On the other hands, three variables were significantly associated with poor survival time in those with AEGJ: ECOG PS C 2, the presence of liver metastasis, and absence of lung metastasis. The independent prognostic factors identified by the multivariate analysis are all significant prognostic factors identified by univariate analysis. The results of multivariate analysis for prognostic factors in patients with AEGJ and GAC are shown in Table 3 . Poor PS was an independent prognostic factor in patients with both AEGJ and GAC. However, there were some differences in prognostic factors between AEGJ and GAC. In patients with GAC, inoperably advanced disease status, diffuse histopathology, and increasing number of metastatic sites influenced survival. The presence of liver metastasis and absence of lung metastasis were also associated with poor prognosis in those with AEGJ.
Discussion
This study first reported from Asia that the clinicopathological characteristics of inoperably advanced or recurrent AEGJ, including sex, tumor location, and histological type, were similar to those of operable AEGJ previously reported in Japan and also in Western countries [8, [16] [17] [18] [19] [20] .
Lung metastasis was diagnosed in 7-41 % of the patients with advanced esophageal cancer, and its frequency was high compared with about 5 % of patients diagnosed with advanced gastric cancer [12, [21] [22] [23] . Because of invasion to the esophagus, AEGJ may have the same drainage system of a vein as lower esophageal cancer. Additionally, it was reported that the mediastinal lymph node metastasis rate of gastric cancer depended on the length of esophageal invasion, and a length of more than 2-3 cm was a risk factor [22, 24] . On the other hand, patients with AEGJ had little peritoneal metastasis because of its anatomical location and histology. Most type I and II AEGJs are not fully covered by the peritoneum. Moreover, peritoneal metastasis was more frequent in patients with diffuse-type histopathology compared to those with intestinal type, the primary histopathological type of AEGJ.
Our data showing that patients with AEGJ have significantly more lung metastasis, more mediastinal lymph node metastasis, and less peritoneal metastasis than patients with gastric cancer are consistent with those of previous reports. The median survival time of patients with advanced AEGJ was 13.0 months, and there was no significant difference in survival between the patients with AEGJ and those with GAC (p = 0.445) in our analysis. In the patients treated with the F ? P chemotherapy regimen, the OS was not significantly different between AEGJ and GAC (p = 0.352). These survival data for the patients receiving F ? P is almost the same as those for inoperable gastric cancer patients who were enrolled and received F ? P in Japanese phase III trials [11] [12] [13] . We identified poor PS, the presence of liver metastasis, and absence of lung metastasis as baseline prognostic factors in patients with inoperably advanced or recurrent AEGJ. Several studies have identified prognostic factors for patients with metastatic gastric cancer who received first-line chemotherapy: poor PS, the presence of liver, peritoneal, or bone metastases, microscopically scirrhous type tumors, and number of metastatic sites [25, 26] . Chau et al. [27] also elucidated that poor PS and the presence of liver or peritoneal metastases was associated with poor prognosis for patients with advanced esophageal, EGJ, and gastric cancer. The prognostic factors in AEGJ identified in our report are compatible with the prognostic factors reported in EGJ and gastric cancer.
Chau et al. [8] reported that the survival curves of patients with advanced AEGJ and GAC almost overlapped and so it might not be necessary to distinguish patients with advanced esophagogastric adenocarcinoma according to primary tumor origin. Our results were consistent with this report. We consider that the same chemotherapy can be given to both patients with inoperably advanced or recurrent AEGJ and those with GAC in the clinical practice in Japan, and Japanese future trials on gastric cancer chemotherapy can include both subgroups.
This study had several limitations because it was a retrospective, single-institution study. First, because the selection of chemotherapy regimen in patients with AEGJ was not standardized, the study included several chemotherapy regimens and tumor location itself might have influenced regimen selection, although differences were not statistically significant. Second, disease progression was judged by the investigators in this study.
In conclusion, we identified that the incidence, characteristics, treatment outcomes, and prognosis for patients with AEGJ showed no significant differences compared with those for patients with GAC. We consider that Japanese future trials on gastric cancer chemotherapy can include both subgroups. 
